Treatment of Chronic Hepatitis C in a Patient Affected by Systemic Sclerosis by Poggi, Guido et al.
Hindawi Publishing Corporation
Gastroenterology Research and Practice
Volume 2009, Article ID 475390, 5 pages
doi:10.1155/2009/475390
Case Report
TreatmentofChronicHepatitisCinaPatientAffectedby
Systemic Sclerosis
GuidoPoggi,1 LauraVillani,2 Federico Sottotetti,1 BarbaraTagliaferri,1
Benedetta Montagna,1 AlessioAmatu,1 andGiovanniBernardo1
1Department of Oncology, IRCCS Maugeri Foundation, via Maugeri 8, 27100 Pavia, Italy
2Department of Pathology, IRCCS Maugeri Foundation, via Maugeri 8, 27100 Pavia, Italy
Correspondence should be addressed to Guido Poggi, guido.poggi@fsm.it
Received 7 May 2009; Revised 20 August 2009; Accepted 16 October 2009
Recommended by Fabio Marra
The currently recommended treatment for patients infected with hepatitis C virus (HCV) is pegilated interferon α (IFN α)p l u s
ribavirin. Despite the numerous beneﬁts of this therapy, there is an increasing concern regarding his tolerance. Among the most
common side eﬀects, interferon may trigger the onset or exacerbation of autoimmune diseases. When chronic hepatitis C coexists
with an autoimmune disorder, it is not clear whether using interferon is better than avoiding it. We evaluated the disease state of a
55-yearoldfemaleaﬀectedbysistemicsclerosis(SSc),duringandaftertherapywithIFNαpegilatedplusribavirinforchronicHCV
infection. We were worried about the potential worsening of the autoimmune disease during the therapy, but we were conﬁdent
that we would give our patient a short course of peginterferon and ribavirin. A mild, asymptomatic worsening of lung SSc was
observed during IFN administration, without life threatening symptoms. After 24 months follow up we observed the maintenance
of the virological response and a good control of the rheumatological disease. Thus, in liver disease at high risk of progression and
concomitant SSc, the antiviral therapy with IFNα is a feasible approach.
Copyright © 2009 Guido Poggi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The currently recommended treatment for patients infected
with hepatitis C virus (HCV) is pegylated interferon α plus
ribavirin [1].
Despite the numerous beneﬁts of interferon-based ther-
apies, there is an increasing concern regarding its tolerance.
Around 12% of patients on therapy cease treatment due to
adverse eﬀects and 2% do so as a consequence of laboratory
abnormalities [2]. Among the most common side eﬀects,
interferon may trigger the development of autoantibodies in
about 50% of patients, or even the onset or exacerbation
of autoimmune diseases in 2% of them. So when chronic
hepatitis C (CHC) coexists, in the same patient, with an
autoimmunedisorder,itisnotclearwhetherusinginterferon
is better than avoiding it.
Several cases of Systemic sclerosis (SSc) developed simul-
taneously with the use of interferon α are described in the
literature, suggesting its promoting role in the occurrence
of the disease [3–5], but nothing is reported about the
treatment of CHC with INF α in patients already aﬀected by
SSc. In this paper we describe the clinical course of a patient
aﬀected by SSc during and after the six-month peginterferon
α and ribavirin therapy for CHC. Systemic sclerosis (SSc) is
a systemic complex connective tissue disease characterized
by the deposition of excessive amounts of normal extra-
cellular matrix components, particularly collagen, in the
skin, subcutaneous tissue, muscles, and internal organs. The
etiology of SSc is unknown but oligoclonal T-cell expansion,
suggestive of an antigen-driven process, and an increase in
theproductionofﬁbrogeniccytokinesplayanimportantrole
in the development of this disease [6].
2.CaseReport
A 55-year-old woman was seen at our hospital because
of elevated alanine aminotrasferase (ALT) and asparatate
aminotrasferase (AST). She had been diagnosed as having
chronic hepatitis C virus infection approximately 10 years2 Gastroenterology Research and Practice
Table 1: Disease activity parameters.
Variable
3m o n t h s
before IFN
therapy
2m o n t h s
before IFN
therapy
1m o n t h
before IFN
therapy
1w e e kb e f o r e
IFN therapy
4th weeks of
therapy
At the end of
IFN
24 months
after IFN
FVC (% predicted) +0% −10% +0%
DLCO (% predicted) −29% −40% −20%
White cells count × 109 73 . 2 6 . 6
Red cells count × 1012 4.66 4.2 4.62
Hg (g/dl) 13.4 12 13
Platelet count × 109 215 194 243
RCP 0.34 0.3 0.3
Creatinine (mg/dl) 0.89 0.6 0.7
ALT (IU/L) 857 437 237 241 36
AST (IU/L) 424 291 156 168 36
AP (IU/L) 422 344 291 275
GGT (IU/L) 288 187 115 110
Bilirubin (mg/dl) 0,4 0.4 0.3 0,3
HCV-RNA viremia (IU/ml) 3131760 <50 <50 <50
earlier, in 1996. The viral genotype was 2a/2c. ALT and AST
values were in the normal range at diagnosis and remained
normal throughout bi-annual followups. Liver biopsy gave
a diagnosis of chronic hepatitis with minimal activity and
absence of ﬁbrosis (A1, F0, Metavir). No antiviral therapy
was planned and the patient was advised to continue the
monitoring of her liver enzymes.
Five years after this ﬁrst evaluation the patient com-
plained of bilateral Raynaud’s phenomenon and morning
stiﬀness. Laboratory tests showed the presence of antinu-
clear antibody (ANA) (1 : 640) with centromeric pattern.
Cryoglobulins were not detectable in serum. A scleroderma
pattern was observed by capillaroscopy while pulmonary
function tests were normal, showing only a mild reduction
in the diﬀusing capacity of carbon monoxide (DLCO, 60%
predicted). No interstitial lung disease was found by high-
resolution computed tomography, and echocardiography
showed normal left ventricular systolic function. Bron-
choalveolar lavage ﬂuid was normal. According to clinical
and laboratory ﬁndings the patient was diagnosed as having
mild SSc with cutaneous and pulmonary involvement, with-
out pulmonary hypertension. Over the next few years the
Raynaud’s phenomenon became somewhat more frequent
and DLCO was slightly decreased.
TenyearsafterthediagnosisofhepatitisCvirusinfection,
hepatic enzymes suddenly increased for the ﬁrst time,
and remained quite elevated during the following months
(Table 1). We decided to perform a liver biopsy that gave
a diagnosis of severe worsening of the chronic hepatitis
compared to the previous biopsy, with marked viral activity
and severe ﬁbrosis (A3, F3, Metavir). No histological clues
addressing the diagnosis of autoimmune hepatitis were
found. Speciﬁcally lobular necrosis and moderate portal
inﬂammation were the predominant aspects of necroinﬂam-
matory activity without evidence of liver cell rosettes or
plasmocytic portal inﬁltration. Although hepatitis C shares
some histological features with autoimmune hepatitis, such
as portal lymphoid aggregates or lymphoid follicles with
germinal centers, they were not found in our patient. Other
routine laboratory analyses were normal except for ANA
test that was positive (1 : 640) with centromeric pattern.
No speciﬁc autoantibodies were detected, including anti-
ENA, anti-dsDNA, antimitochondrial (AMA), antismooth
muscle (SMA), and antiliver-kidney microsomes (LKMs),
antineutrophil cytoplasmic antiobodies (ANCAs), antisolu-
ble liver antigens, and antiliver-pancreas (LP) autoantibod-
ies. HCV viral load was elevated (3.131.400IU/mL). The
calculated score for autoimmune hepatitis, according to the
International Scoring System, indicated a low probability of
disease (Table 2)[ 7]. After an exhaustive discussion with
the patient about pros and cons of treating chronic viral
infection in this peculiar setting of associated connective
tissue disease, the patient decided to receive treatment. The
therapy, consisting in subcutaneous weekly injections of
180μg of peginterferon alfa-2a (Pegasys, Hoﬀman-LaRoche)
plus 800mg daily Ribavirin (Copegus, Hoﬀman-LaRoche),
wasstartedinDecember2005withprogressiveimprovement
of the liver function tests and fast decline of the HCV
viremia.Fourweeksafterthebeginningofthetherapy,serum
transaminases normalized and HCV RNA level, as measured
with the use of a qualitative polymerase-chain-reaction assay
(Cobas Amplicor HCV Test, version 2.0; detection limit,
50IU per milliliter), was undetectable and remained so up
to the end of the treatment (24 weeks). During the therapy
and during the following two years pulmonary functional
tests, capillaroscopy, and rheumatologic evaluations were
performed to detect any worsening of the associated con-
nective tissue disease. The followup was uneventful with
stabilization of Raynaud’s phenomenon and no worsening
of lung function. The patient’s main clinical and laboratory
ﬁndings, before at the end and after 24 months after the end
of therapy, are summarized in Table 1.Gastroenterology Research and Practice 3
Table 2:Internationalscoringsystemfordiagnosisofautoimmunehepatitis.Thisscoringsystemdeﬁnesa“deﬁnitiveautoimmunehepatitis”
for values >+15 before treatment; “probable autoimmune hepatitis” is deﬁned for values between 10, and 15 before treatment. Our patient
presented total score +5 (very unlikely diagnosis of autoimmune hepatitis).
Parameter Patient’s results Score Parameter Patient’s results Score
Gender Female +2 Hepatotoxic dugs exposure No +1
AP : AST ratio <3.0 +2 Alcohol <25g/day +2
γ-globulin level above-normal 1.0–1.5 +1 HLA DR3 o DR4 No 0
Autoantibodies ANA > 1 : 80 +3 Other autoimmune disease yes +2
Antimitochondrial Antibodies Negative 0 Other markers Negative 0
Viral markers HCV RNA positive −3 Histological features None −5
AP : AST ratio: ratio of alkaline phosphatase level to aspartate aminotransferase level; ANA: antinuclear antibodies.
Table 3: Case reports from literature.
Age Gender IFN Pathology Dose Duration
Timing of
disease
appearance
Therapy Trend
Author, year
and
references
66 Female INFαcon-1 Chronic viral
hepatitis
18 MIU/daily
for 2 weeks
than 18
MIU/three
times weekly
20 weeks
1 year after
the end of
IFN therapy
Tocopherol
nicotinate
Partial relief
with
recurrent
disease
Tahara et al.
[5]
47 Female INFα2b Chronic viral
hepatitis
3 MIU/three
times weekly
Interrupted
after 6
months
During
therapy
Interruption
of IFN
therapy and
prednisone
1mg/kg/day
Limited form
of systemic
sclerosis
Solans et al.
[3]
52 Female INFα2a
Chronic
myelogenous
leukaemia
6 MIU/daily 25 months During
therapy
Loop
diuretics,
cyclophos-
phamide
100mg/day,
prostanoids,
steroids
Partial
improvement
Beretta et al.
[4]
3. Discussion
Clinical studies on IFNα in the pathogenesis of autoimmune
diseases have given contradictory results, either its detrimen-
tal or its protective role being suggested.
IFNα is of potential beneﬁt in reducing ﬁbrosis [8]
since it has been shown to inhibit skin collagen synthesis
and ﬁbroblast proliferation, in vitro [9]. IFNα is also able
to reduce the transforming growth factor β1( T G F β1)
messenger RNA when used in the treatment of chronic liver
disease [10]. All the interferons have also been reported
to be beneﬁcial in the treatment of a variety of ﬁbrotic
diseases, including scleroderma [11]. IFNα therefore may
be an appropriate treatment to retard ﬁbrosis in early
scleroderma. Despite such evidence, the results of a random-
ized, double blind, placebo-controlled clinical trial failed
to show any improvement of the outcome in patients
with diﬀuse cutaneous scleroderma treated with interferon
[8].
Other studies focused on the role of cytokines, par-
ticularly type I IFNα and IFNβ, in the development and
perpetuation of autoimmunity [12].
IFNα-basedtherapieshavebeenusedforthetreatmentof
speciﬁc malignancies and for treating chronic viral hepatitis
Ca n dB[ 13]. The mechanism of its activity is likely based on
the capacity of exogenous IFNα to promote cellular eﬀector
functions that are mediated by cytotoxic T lymphocytes and
natural killer cells. Furthermore, exogenous cytokines play
a role in modulating dendritic cells activation and in the
priming of na¨ ıve T cells.
Autoimmunity is a fairly common complication of
IFN-based treatments, as indicated by several case reports
that describe the development of autoimmune thyroid
diseases,diabetes,SLE,polymyositis,psoriasis,inﬂammatory
arthritis, Sjogren’s syndrome, and Crohn’s disease [14],
particularly in the absence of predicting factors such as
the presence of autoantibodies before the beginning of the
therapy. During IFNα treatment, more than 50% of subjects
develop autoantibodies, but only 1-2% show an evident
autoimmune pathology [15, 16].
Systemicsclerosis(SSc)isaconnectivetissuemultisystem
disease, whose pathogenesis involves autoimmune phenom-
ena, alteration of microvasculature and massive deposits
of collagen, and other matrix substances in the connective4 Gastroenterology Research and Practice
tissue. Dysregulation of humoral immunity in SSc is best
represented by the variety of autoantibodies against nuclear
and nucleolar components, spontaneously produced by SSc
patients, some of which are highly disease speciﬁc. In
addition, recent reports suggest that antitopoisomerase anti-
bodies directly bind ﬁbroblasts, and that their serum levels
correlate with SSc disease activity [17]. Abnormalities in
cellular immunity are apparent from the increased number
of T cells that bear markers of activation in peripheral blood
of SSc patients.
In the literature, we have found only three cases of SSc
occurring in female patients during or after treatment with
IFNα. Two of them were treated for chronic hepatitis C
and one for chronic myelogenous leukemia. The association
between IFNα therapy and appearance of SSc has been
stronglydemonstratedonlyinoneofthesepatients(Table 3).
Conversely there are no reports in the literature on the
clinical outcome of patients formerly aﬀected by SSc who
received IFNa for chronic viral hepatitis C.
In our case report we evaluated the disease state of a 55-
year-old female aﬀected by SSc, during and after antiviral
therapy with IFNα pegilated plus ribavirin for chronic viral
hepatitis C.
It is well known that a sudden ﬂare up of serum
transaminase, particularly in genotype 2 or 3 hepatitis C,
leads to severe worsening of liver ﬁbrosis. This also happened
to our patient [18, 19], and prompted us to start an antiviral
therapy. We were worried about the potential worsening
of the autoimmune disease during therapy with interferon,
but we were conﬁdent that we would give our patient a
short course of peginterferon and ribavirin. Indeed, data
published short time before had shown no diﬀerence in
viral clearance between short and conventional therapies in
genotype 2 or 3 chronic hepatitis [20]. Furthermore, IFN has
been tested also in patients with rheumatic disease, showing
controversial outcomes, as demonstrated by Nissen et al.
in their 2005 study, in which patients treated with inter-
feron α for HCV with rheumatological symptoms showed
deterioration in 50% of cases, no changes in 33%, and
amelioration in 17% [21]. More encouraging results were
reported by Zuckerman et al. who demonstrated a complete
or partial response of arthritis related symptoms in 44%
of 25 HCV arthritis patients treated with interferon α The
authors concluded that interferon α may lead to substantial
clinical improvement of HCV related arthritis even without
a complete biochemical or virological response [22].
We therefore decided to start an antiviral therapy with
IFNα and ribavirin in our patient, despite her concomitant
disease. During the therapy the patient underwent frequent
followup visits. A mild, asymptomatic, and temporary wors-
ening of lung SSc was observed at instrumental tests during
IFN administration (decreased FVC%, decreased DLCO),
in the absence of life threatening symptoms or severe
discomfort. Black et al. pointed out that IFNα therapy might
be deleterious in SSc patients since it exacerbates symptoms
and precipitates lung deterioration through the upregulation
of the intercellular type I adhesion molecule (ICAM1), a
ﬁbroblast adhesion molecule that is overexpressed in SSc
ﬁbroblasts and is believed to be important in mediating
lymphocyte-ﬁbroblast interactions [23]. In all the cases of
SSc developed during treatment with inducing drugs, such
as docetaxel, bleomycin, and other chemotherapeutic agents
[24] the discontinuation of the treatment improved or
reversed SSc symptoms. Also in our patient, at the end of the
treatment, we observed a progressive normalization of lung
function parameters, that soon returned to pretreatment
values.
After 24 months of followup, we observed the mainte-
nance of the virological response and a good control of the
rheumatological disease. In conclusion, IFNα was eﬀectivein
ourpatient,leadingonlytoanasymptomaticmildworsening
of SSc. Thus, in liver disease at high risk of progression and
concomitant SSc, the antiviral therapy with IFNα is a feasible
approach.
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